INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 184 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $498,000 | -80.6% | 20,157 | -67.5% | 0.05% | -79.6% |
| Q3 2020 | $2,573,000 | +36.9% | 62,053 | +58.2% | 0.24% | +100.8% |
| Q2 2020 | $1,880,000 | +2.4% | 39,235 | +34.6% | 0.12% | -24.2% |
| Q1 2020 | $1,836,000 | -82.1% | 29,158 | -64.8% | 0.16% | -80.8% |
| Q4 2019 | $10,268,000 | +31.6% | 82,862 | -29.5% | 0.84% | +57.6% |
| Q3 2019 | $7,800,000 | – | 117,543 | – | 0.53% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |